These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 12181399)

  • 1. A molecular star in the wars against cancer.
    Schwartz R
    N Engl J Med; 2002 Aug; 347(7):462-3. PubMed ID: 12181399
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
    N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Philadelphia chromosome-negative myeloproliferative neoplasm with a novel platelet-derived growth factor receptor-β rearrangement responsive to imatinib.
    Cornfield D; Shah U; Cross N; Bennett C; Sun G
    J Clin Oncol; 2012 Mar; 30(9):e109-11. PubMed ID: 22331939
    [No Abstract]   [Full Text] [Related]  

  • 4. Chronic myeloproliferative disorder with ETV6-PDGFRβ fusion gene.
    Tipirneni E; Buttar A; Brettler D; Miron P; Bathini V
    Ann Hematol; 2012 Apr; 91(4):637-8. PubMed ID: 21833478
    [No Abstract]   [Full Text] [Related]  

  • 5. Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders.
    Gallagher G; Horsman DE; Tsang P; Forrest DL
    Cancer Genet Cytogenet; 2008 Feb; 181(1):46-51. PubMed ID: 18262053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms.
    Hidalgo-Curtis C; Apperley JF; Stark A; Jeng M; Gotlib J; Chase A; Cross NC; Grand FH
    Br J Haematol; 2010 Jan; 148(2):268-73. PubMed ID: 20085582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia.
    Medves S; Duhoux FP; Ferrant A; Toffalini F; Ameye G; Libouton JM; Poirel HA; Demoulin JB
    Leukemia; 2010 May; 24(5):1052-5. PubMed ID: 20164854
    [No Abstract]   [Full Text] [Related]  

  • 8. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
    Cross NC; Reiter A
    Acta Haematol; 2008; 119(4):199-206. PubMed ID: 18566537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
    Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
    Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report.
    Pitini V; Arrigo C; Teti D; Barresi G; Righi M; Alo G
    Haematologica; 2003 May; 88(5):ECR18. PubMed ID: 12745287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease.
    Curtis CE; Grand FH; Waghorn K; Sahoo TP; George J; Cross NC
    Leukemia; 2007 Aug; 21(8):1839-41. PubMed ID: 17508004
    [No Abstract]   [Full Text] [Related]  

  • 12. [The tyrosine kinase antagonist imatinib mesylate].
    Heinzl S
    Med Monatsschr Pharm; 2002 Jan; 25(1):4-7. PubMed ID: 11826665
    [No Abstract]   [Full Text] [Related]  

  • 13. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
    Cortes J; Kantarjian H
    Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).
    Levine RL; Wadleigh M; Sternberg DW; Wlodarska I; Galinsky I; Stone RM; DeAngelo DJ; Gilliland DG; Cools J
    Leukemia; 2005 Jan; 19(1):27-30. PubMed ID: 15496975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New oncological treatment principle with imatinib].
    Kuenen BC; Pinedo HM
    Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.
    Weston BW; Hayden MA; Roberts KG; Bowyer S; Hsu J; Fedoriw G; Rao KW; Mullighan CG
    J Clin Oncol; 2013 Sep; 31(25):e413-6. PubMed ID: 23835704
    [No Abstract]   [Full Text] [Related]  

  • 17. [Tyrosine kinase inhibitor as a targeted therapy for GIST tumors].
    Joensuu H
    Duodecim; 2002; 118(22):2305-12. PubMed ID: 12523107
    [No Abstract]   [Full Text] [Related]  

  • 18. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement.
    Arefi M; García JL; Peñarrubia MJ; Queizán JA; Hermosín L; López-Corral L; Megido M; Giraldo P; de las Heras N; Vanegas RJ; Gutiérrez NC; Hernández-Rivas JM
    Eur J Haematol; 2012 Jul; 89(1):37-41. PubMed ID: 22587685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Myeloproliferative neoplasms and related diseases].
    Kirito K
    Rinsho Ketsueki; 2009 Mar; 50(3):134-46. PubMed ID: 19352079
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of advanced gastrointestinal stromal tumor: a marriage of targeted therapy and surgery?
    DeMatteo RP
    Ann Surg Oncol; 2007 Jan; 14(1):1-2. PubMed ID: 16957967
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.